🇺🇸

Broad Market

· daily

US SEC Filings Daily Market Digest — May 13, 2026

Across 50 SEC filings for May 13, 2026, key themes include robust SPAC activity with multiple IPOs (Starlink AI, West Enclave) raising $200M+ and extensions (Aquaron, GP-Act III), signaling renewed M&A appetite in a potentially frothy market. Q1 2026 10-Qs reveal polarized performance: 14/22 reporting companies posted YoY revenue growth averaging 85% (outliers like SS Innovations +117%, SOLV Energy +66%), but 18/22 widened net losses amid SG&A surges (e.g., SOLV non-cash comp +8,300%), highlighting growth-at-all-costs in small caps/biotechs. Annual meetings (10+ filings) overwhelmingly passed director elections, say-on-pay, and auditor ratifications with >90% support, indicating stable governance. Biotech/health firms (Anteris, Azitra, Zenas) advanced trials with capital raises extending runways to 2029, while consumer/retail showed resilience (National Vision +6.6% rev, +4.4% comp sales). Capital allocation leans shareholder-friendly: Expensify $25M tender, News Corp $1B buyback authorization. Portfolio-level: Margin expansion rare (National Vision +150bps adj op margin), but cash burns average $4M/Q in loss-makers; forward catalysts cluster in H2 2026 trials/data readouts. Implications: Favor disciplined growers like National Vision/Cigna; monitor SPAC redemptions and biotech burn rates for downside risks.

31 high priority 19 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 13, 2026

Across 50 pre-analyzed US SEC and global filings for May 13, 2026, mixed sentiment dominates (70% of filings), with stark contrasts between revenue growth in industrials/tech (e.g., Astronics +12% YoY sales, AmpliTech +49% revenue) and deepening losses/cash burns in biotechs/pharma (Semnur op ex +588% YoY) and crypto ETFs (NAV drops 18-40% QoQ amid unrealized depreciation). Period-over-period trends reveal portfolio-level margin compression averaging -100 bps in financials/REITs (LIC Housing NIM -5 bps, Bogota non-int inc -64% YoY), offset by capital returns like Cybertech's 2.73% buyback at ₹170/share and LIC's 500% dividend. Critical developments include Radhagobind's ongoing CIRP insolvency (8th COC meeting May 15), HF Sinclair CFO termination, and Nuvve's dilutive warrant exchange needing approval by July 27; crypto ETFs show crypto price sensitivity with Canary XRP/Solana NAV -18%/-40% QoQ. Sector themes highlight biotech cost-cutting (R&D -30-70% YoY in Spruce/Dermata) amid cash raises, while buybacks/dividends signal conviction in software/financials. Implications: Near-term alpha in buyback catalysts and turnarounds, but watch distress in microcaps/insolvencies for downside risks.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 13, 2026

Overnight SEC filings from May 12-13, 2026, reveal a mixed Q1 2026 earnings landscape across 50 reports, with standout revenue growth in small-caps like SS Innovations (+117% YoY), SOLV Energy (+66% YoY), and ASIAFIN (+105% YoY), contrasted by declines in DarioHealth (-17% YoY), Hughes Satellite (-11% YoY), and Spectral AI (-40% YoY R&D revenue). SPAC activity surges with new IPOs (Starlink AI $100M, West Enclave $115M total), extensions (Aquaron to 2027, GP-Act III to Nov 2026), and non-redemptions boosting deal prospects. Annual meetings dominate with strong approvals (Lockheed Martin 86% quorum, Innospec 91%), signaling governance stability, while capital allocation favors buybacks (News Corp $1B program), tenders (Expensify $25M), and debt refinancings (Tempus AI $350M notes, SOLV post-IPO paydown). Biotech firms like Zenas, Anteris, and Azitra report widened losses from R&D but bolstered cash via raises ($320M Anteris, $419M Zenas), extending runways to 2029. Portfolio trends show margin expansions in National Vision (+760 bps adj op margin to 10.2%) and Regis (+improved op income despite -8% rev), but compressions elsewhere; forward catalysts cluster in H2 2026 trials/data readouts. Implications: Bullish for SPACs and growth small-caps pre-market, cautious on biotechs with burn rates, watch guidance reaffirms like Cigna's $30.35 EPS.

31 high priority 19 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 12, 2026

Across 50 US SEC filings from May 12, 2026, dominant themes include widespread executive transitions (24 cases, ~48% orderly retirements/appointments signaling continuity), robust annual meeting approvals (17 filings, avg 90%+ support for directors/equity plans/auditors), aggressive financing (18 cases: debt refinancings, equity raises, facilities with lower rates/costs), and M&A/JV activity (12 deals, total ~$2.5B+ value). Period-over-period trends show strong revenue acceleration in industrials/energy/semiconductors (e.g., SOLV +66% YoY Q1 rev to $677M, Arteris +39% YoY to $22.9M, Nextpower +20% FY26 to $3.56B) but mixed margins (improvements in SOLV gross +310bps to 17.6%, compressions in OptimizeRx amid macro pressures). Guidance upgrades in 7 firms (e.g., SOLV EBITDA $435-455M, Collegium rev $865-895M) contrast isolated downgrades/dilution risks; biopharma mixed with trial misses offset by partnerships (Arvinas $85M upfront). Portfolio-level: Semis/tech resilient (positive sentiment 80%), financials bolstering liquidity, health sector catalyst-rich but volatile; implies bullish rotation to growth industrials, caution on leadership-vacant energy.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 12, 2026

The May 12, 2026, SEC filings reveal a deluge of 13F-HR reports (over 30) from global institutions, showcasing overwhelming conviction in US tech giants like NVIDIA, Apple, Amazon, and semiconductors, with portfolio concentrations up to 43% in single names like AAPL, signaling sustained bullishness amid AI hype. Earnings and operational 8-Ks present mixed pictures: aerospace/defense names like Ducommun posted record revenue (+9% YoY) and margin expansion (+70 bps), while electronics firms like Qnity saw sales surge (+18% YoY) and raised FY guidance despite GAAP EPS drops. Capital markets activity thrives with IREN's $2.6B convertible notes pricing (positive) and eBay's rejection of GameStop's $20B bid, affirming standalone strength. Risks emerge in niche areas: BETA Technologies' losses widened dramatically (net loss to $122M from $78M YoY), Next Bridge Hydrocarbons reported revenue declines (-11% YoY) with zero reserves, and Maison Solutions faces Nasdaq delisting risk for missing annual meeting. Forward guidance leans optimistic in select industrials (e.g., Optex FY revenue up to $45M), but consumer segments weaken (Green Dot GDV -8% YoY). Portfolio-level trends highlight margin resilience in defense (+70 bps avg across Ducommun/Optex) versus compression elsewhere, positioning aerospace as a relative outperformer amid industrial softness.

6 high priority 44 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 12, 2026

Across 50 filings in the 'Global High Priority Market Events' stream (US SEC and Indian exchanges, dated May 12, 2026), dominant themes include multiple corporate insolvencies and restructurings in Indian firms (e.g., Morarjee Textiles resolved, Arshiya with ₹67B claims), positive buyback announcements (Onward Technologies ₹18Cr, Garware ₹110Cr), and mixed Q1 2026 results with revenue growth averaging +35% YoY in outperformers like Rocket Companies (+167%) and SOLV Energy (+66%) but declines in consumer-facing names like Sleep Number (-19%). Period-over-period trends show 18/25 10-Qs with YoY revenue growth (avg +44% in positives), but margin compression in 12 cases (avg -150bps in mixed sentiment firms); capital allocation leans bullish with buybacks and dividends up YoY (e.g., Sound Financial +11% dividend). Critical developments: NCLT resolutions/takeovers (AVI open offer at ₹33/share), SPAC amendments, and raised guidance (SOLV EBITDA to $435-455M). Portfolio implications: Favor buyback plays and strong Q1 industrials amid insolvency risks in India; sector rotation toward semis/energy with hedges on consumer weakness.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 12, 2026

Overnight SEC filings for May 11-12, 2026, are dominated by 37 13F-HR reports revealing strong institutional conviction in mega-cap tech (Apple, NVIDIA, Amazon topping 20+ portfolios, avg 20-40% allocation), signaling sustained bullishness on AI/semiconductors amid no reported changes from Q1 2026. Earnings releases show mixed Q1 2026 results: 5/7 reporting companies achieved revenue growth averaging +11% YoY (Ducommun +9%, Qnity +18%, Green Dot +17%), but margins varied (+70bps Ducommun to compressions elsewhere) and losses widened in high-growth names like BETA (+5.6% rev but -56% net income YoY). Guidance trends positive with raises (Qnity FY sales $5.225-5.375B, Optex FY rev $43-45M up from $41.3M), offset by widened loss outlooks (BETA Adj EBITDA -$355-445M). Capital raises prominent (IREN $2.6B notes due 2033, UGI €300M notes), exec transitions neutral-to-positive (Diodes new Chair, Astrana CMO resignation), and risks in compliance (Maison Nasdaq violation). Sector themes highlight aero/defense resilience, electronics outperformance, and heavy foreign investor tech bets; actionable now: buy electronic/aero dips pre-catalysts, monitor tech overweight for rotation risks.

6 high priority 44 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 11, 2026

Across 50 SEC filings from May 11, 2026, the dominant theme is extensive executive churn with 20+ resignations (mostly neutral, no disagreements) and 15+ appointments/promotions, signaling potential leadership stabilization or transitions in tech, finance, and industrials amid a stabilizing market. SPAC activity surges with 3 new IPOs priced at $100M each (Shreya, Vernal), alongside M&A like Apollo's $1.5B Emerald acquisition at 42% premium and Resideo's Q3/Q4 ADI spin-off unlocking $4.8B revenue segment. Financial results are mixed: Cronos +40% YoY revenue standout vs FSK/ZoomInfo declines (NAV -10% QoQ, guidance cut 5%), with aggregate revenue growth in reporting firms averaging +20% YoY but margins compressing -1-2pp in 3/5 cases. Capital allocation leans shareholder-friendly: $300M FSK buyback/tender, Cronos $50M repurchase renewal, multiple financings ($450M Credit Acceptance, $725M McGrath). No widespread insider trading data, but positive guidance in Faraday (1,000 robots 2026) and strong annual meeting approvals (UPS, Alcoa) point to resilient governance. Portfolio-level, finance/BDCs show stress (higher debt ratios), while SPACs/healthcare offer entry points; watch Q2 catalysts like FSK tender (May 12) and Resideo investor day (mid-July). Overall, actionable now: favor spin-offs/M&A over pure earnings reporters.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 11, 2026

Across 50 SEC filings for May 11, 2026, a dominant theme is mixed financial performance with robust revenue growth in energy services (e.g., NESR +33.5% YoY, Kodiak +6.2% YoY) contrasting weakness in media/advertising (Townsquare -1.9% YoY) and select tech/consumer segments, amid 11.6% YoY revenue gains at Dole but EBITDA declines. Period-over-period trends show 18/25 quarterly reporters with YoY revenue growth averaging +25% in energy/oil vs. -5% in media, though margins compressed in 12 companies (avg -100 bps) due to impairments/expenses; net income swings positive in 10 firms via tax benefits or cost controls. Capital allocation leans shareholder-friendly with dividends/buybacks in 9 firms (e.g., NESR $0.10/share dividend + $50M repurchase), while forward-looking guidance raised in 5 (Kodiak EBITDA to $820-860M, Seadrill revenues $1.43-1.48B). Institutional 13Fs reveal concentrated bets on STAA, LU, API; IPO/SPAC momentum with EagleRock's Permian surge (308% YoY rev) and Shreya's $100M pricing signals M&A/expansion alpha. Portfolio-level, energy outperforms (avg +40% YoY EBITDA in 4 firms) vs. BDCs/REITs lagging; watch Q2 catalysts like NESR dividends and Kodiak power capacity adds for rotational trades.

29 high priority 21 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 11, 2026

The 50 filings reveal a surge in Indian insolvency resolutions and neutral SEBI regulatory confirmations (not Large Corporates) across 15+ companies, signaling compliance but low operational impact, alongside high-materiality US events like SPAC IPOs, M&A updates, and mixed Q1 2026 10-Qs. Aggregate period trends show revenue growth in 12/25 US filers averaging +25% YoY (e.g., NESR +33.5%, Dole +11.6%, Gold.com +244%), but 14 reported widening losses or impairments due to non-cash charges, margin compression (avg -150bps in media/tech), and high debt; banks like Prosperity (+13% assets) and Western Alliance (+6.5% assets) expanded via M&A/deposits. Insolvencies dominate critical events: Morarjee Textiles plan orally approved (positive), SKIL Infrastructure critically weak (negative). Capital allocation leans shareholder-friendly with dividends/buybacks in 8 firms (e.g., Carlyle $28M divs +$18M repurchases), but cash burns persist in biotech/energy. SPACs raised $300M+ (Shreya $100M, Quantum Leap $200M), flagging M&A catalysts. Portfolio implication: Opportunistic buys in turnaround energy/produce amid volatility; avoid distressed insolvencies without resolution catalysts.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 11, 2026

Across 50 overnight SEC filings for May 10-11, 2026, dominant themes include robust revenue growth in energy services (e.g., NESR +33.5% YoY, Kodiak +6.2% YoY, averaging 25%+ across 6 firms) offset by margin compression and losses in media/produce (Townsquare -1.9% YoY revenue, Dole op income -8.7%). Mixed sentiments prevail in 70% of earnings reports, with 12/20 Q1 10-Qs showing YoY revenue growth but 8 noting EBITDA/operating declines averaging -5-10%. Capital allocation trends favor shareholder returns: 10 firms declared dividends (e.g., NESR $0.10 Q4 start, Carlyle $0.35 Q2) and 5 announced buybacks (totaling $175M+ authorizations). Guidance raises in energy (Kodiak FY EBITDA $820-860M up, Seadrill rev $1.43-1.48B up) signal sector strength amid M&A/IPOs (EagleRock IPO with 308% rev surge pro forma, QXO-TopBuild pending). 13F filings reveal neutral institutional positioning in tech/energy names. Portfolio-level: Energy outperforms (avg +20% YoY rev vs consumer -2%), with catalysts like earnings calls today driving pre-market action.

29 high priority 21 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 08, 2026

Across 50 SEC 8-K filings dated May 8, 2026, dominant themes include annual shareholder meetings (15+ companies) with near-universal approval of directors, auditors, and compensation (avg 90%+ For votes), signaling strong governance alignment; executive transitions (20+ cases) mixing neutral resignations and positive appointments; and capital raises/financings ($35M biotech, $20M aircraft, $1.1B data center contract) funding growth amid limited PoP financial data. No broad revenue/margin PoP trends emerge due to event-focused filings, but positive trial data (Cellectar 83.6% ORR) and deal upgrades (Two Harbors merger to $12/share, +6.2%) highlight growth catalysts. Critical developments: Digi Power X's $2.5B potential AI data center deal and Cannabist's CCAA bankruptcy/asset sale signal sector divergence in tech/biotech vs cannabis distress. Portfolio implications favor small-cap growth names with funding (8/50 positive financings) over governance risks (e.g., Permian Basin indenture easing to majority vote). Overall positive sentiment (24/50 positive/neutral tilt) with M&A acceleration and board refreshes boosting conviction.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 08, 2026

Across 50 SEC filings for May 8, 2026, mixed Q1/FY results dominate with 70% showing revenue growth (avg +15% YoY in high performers like Cloudflare +33.5%, Monster +26.9%, Astrana +56%) but frequent profitability pressures from higher opex/costs (e.g., 8/15 quarters with wider losses, avg operating margin compression -150bps). Capital allocation trends bullish with 12 companies announcing/raising dividends (e.g., Innospec +10%, Grainger +10%) and buybacks (e.g., News Corp $1B program, Itron $200M new), while financings raised $200M+ in biotech/aero (Cellectar $35M, New Horizon $20M). Energy/mining pivot to AI notable (IREN $3.4B NVIDIA deal), REITs face vacancies dragging AFFO -6% avg. Forward guidance mixed: 6 raises (Grainger EPS +5%, OSS rev +20-25%), 2 cuts/deferrals (Ziff Davis deferred). Portfolio implication: Favor growth names with strong cash flow (e.g., Republic Services OCF +20%), monitor debt rises (Ducommun +25%, IREN convertibles x4). Sector rotation opportunity from traditional energy to AI infra.

21 high priority 29 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 08, 2026

Across 50 filings for May 8, 2026, focused on global high-priority events, dominant themes include mixed Q1 2026 earnings with revenue growth averaging +20% YoY in high performers like Cloudflare (+33.5%), Astrana Health (+56%), and Vistra (+43%) offset by declines in Virtus (-8.4%) and flat Watsco (0.1%), alongside a wave of Indian insolvencies (Quadrant Televentures, Kallam Textiles, Prime Focus, Jindal Poly) signaling distress in textiles/telecom. Capital raises were prominent (Cellectar $35M, New Horizon $20M) funding trials and aircraft programs, while buybacks (Garware Technical Fibres ₹110 Cr, Republic Services $317M) and repurchases (Monster $134M, Yum China $218M) indicate shareholder returns amid mixed margins (compression in 12/20 10-Qs averaging -100 bps). Positive catalysts include Phase 3 trial funding and strong ORR data (Cellectar 83.6%), but risks from delisting threats (Smith Micro Nasdaq extension to June 22) and widening losses (IREN $248M Q3 net loss) prevail. Sector patterns show healthcare/biotech outperformance vs. manufacturing distress; overall sentiment mixed (24/50), with 10 insolvencies/regulatory actions demanding vigilance. Actionable now: Favor growth names with buybacks, avoid Indian insolvency names.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 08, 2026

Across 50 overnight SEC filings for May 7-8, 2026, Q1 2026 results dominate with mixed sentiments (28/50 mixed), showing revenue growth averaging +15% YoY in high performers like Cloudflare (+33.5%), Astrana Health (+56%), and Monster Beverage (+26.9%), but declines in REITs (NewLake -6.8%) and consumer (Nu Skin -12.1%), amid margin compression in 12/20 reporting companies (avg -150bps). Capital allocation trends bullish with 8 dividend declarations/hikes (e.g., Innospec +10%, Grainger +10%) and buybacks (Yum China $218M, Grainger $345M returned), while financings raised $200M+ (Cellectar $35M, Comstock $57.5M). Energy/mining sector volatile with production ramps (Gold Resource +158% AuEq sold) offset by losses (Gran Tierra -$119M), tech pivots to AI (IREN $3.4B NVIDIA deal), and healthcare/biotech catalysts (Cellectar Phase 3 trial funding). Guidance raised in 6 firms (Grainger EPS to $44.25-46.25, Playtika revenue $2.75-2.85B), signaling resilience; portfolio-level trend: op cash flow improved in 14/25 (avg +25% YoY) despite debt rises (Ducommun +25%). Critical implications: Favor growth tech/health over cyclical REITs/energy pre-market; watch AI/energy transitions for alpha.

21 high priority 29 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 07, 2026

Across 50 SEC filings from May 7, 2026, key themes include a wave of executive leadership changes (18 instances, mostly positive appointments like Target Hospitality's AI expert director and Shake Shack's experienced CFO), robust M&A activity (e.g., VSE's $2B accretive acquisition, Catalyst Pharma's $4.1B takeover at 28% premium, Cross Country's $437M take-private), and mixed Q1 2026 earnings with aggregate revenue growth in 12/20 reporting companies (avg +8% YoY) but volume declines in consumer segments (e.g., Post Holdings -10% ex-acquisitions, Joint Corp -4.9% system-wide). Capital raises dominated financings (ProPetro $600M notes, Avalo $405M equity, Ocugen $115M notes), bolstering liquidity amid some impairments (Ring Energy $162M non-cash). No widespread insider selling detected, but buybacks signaled conviction (Post $600M authorization, Life Time 2.2M shares). Healthcare/biotech showed outperformance with positive trial data and deals, while energy/consumer faced margin pressures (avg -100bps in 5 firms). Portfolio implication: Favor M&A targets for spreads, monitor consumer volume trends for shorts.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 07, 2026

Across 50 SEC filings for May 7, 2026, Q1 2026 results dominate with 28/50 showing revenue growth averaging 28% YoY (outliers like Amcor +77%, Celsius +138%, GigaCloud +32%), but profitability mixed as 18/28 reported EPS declines or margin compression (avg -150 bps in consumer/retail like Arhaus -60% op income). Healthcare/biotech sector shines with Privia +26% rev/guidance raise, LifeStance +21% rev/+48% EBITDA, but faces cash burn (Generate Biomedicines net loss widened). M&A activity surges (Cross Country 31% premium buyout, Gyre $300M Cullgen acquisition, Hennessy SPAC nuclear), alongside aggressive capital returns (12 cos buybacks totaling >$500M, e.g., GigaCloud $12M Q1). Guidance largely reaffirmed/raised (Privia Attributed Lives up, Arhaus FY rev 3.7-6.6%), signaling resilience amid macro challenges; financials show deposit growth but loan/asset contractions (Citizens -2.3% loans QoQ). Portfolio trend: Favor growth stocks with strong guidance over margin-squeezed names; watch Q2 catalysts like deal closes.

18 high priority 32 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 07, 2026

The 50 filings dated May 7, 2026, primarily consist of ~30 10-Q quarterly reports (medium materiality/risk) across sectors like energy (Sandridge, Chord, Peabody), tech (Wolfspeed, Upwork, Hubspot), REITs (CareTrust, Global Medical), and biotech (4D Molecular, IN8BIO, Xenon), signaling the kickoff of Q1 2026 earnings season with no disclosed broad deteriorating trends in revenue or margins from available data. Critical high-materiality events include Carnival PLC's disclosures of delisting, change in control, asset disposition, and agreement termination (high risk, potential takeover/restructuring), Shree Hanuman Sugar's ongoing insolvency with 17th CoC meeting (negative), and Route Mobile's mixed results featuring ₹135.87cr write-offs offset by ₹11/share total dividend. Positive governance themes emerge with Target Hospitality's AI/data center expert board addition, Peabody Energy's strong AGM approvals (86M+ FOR incentive plan), Designer Brands' transformation progress, and SenesTech's new CEO appointment with 5% equity option. Capital market activities feature Entergy's 19.2M share forward sale at $110.74 (dilution risk to 2028), Booking Holdings' $750M 5.375% notes due 2036, and Eloxx Pharma's IPO S-1 filing. Portfolio implications: Watch distress for short/turnaround plays (Carnival, Shree), favor governance strengthens (Target, Peabody), and monitor SPAC catalysts (General Fusion mid-2026 close); neutral overall sentiment with pockets of opportunity in AI/growth and risk in restructuring.

50 high priority 50 total filings
· daily

US Material Events SEC 8-K Filings — May 06, 2026

Across 50 US SEC filings from May 6, 2026, dominant themes include widespread executive transitions (14+ cases of promotions, departures, or appointments, e.g., General Mills COO promotion, Anavex interim CEO), mixed Q1 2026 earnings with average revenue growth of ~10% YoY in reporting firms but frequent margin compressions (e.g., -2750 bps at Energy Recovery, -300 bps at Instacart), and robust capital markets activity via debt issuances/refinancings (e.g., Core Scientific $3.3B notes, Amphenol €1.1B), buybacks (Instacart $349M, Energy Recovery $25M auth), and M&A/divestitures (Broadwind Abilene sale for $19.5M). Portfolio-level trends show 7/12 earnings reporters with YoY revenue growth (avg +12%), but 6/12 with EBITDA/operating losses widening or margins contracting avg -800 bps, signaling cost pressures amid growth. Positive AGMs (90%+ approval rates in Leidos, Mativ) reflect shareholder alignment, while guidance changes are split: 3 raises (908 Devices FY rev to $67-70M), 1 withdrawal (Broadwind). Sector patterns favor energy/financials with liquidity boosts, but tech/biotech shows leadership churn risks. Implications: Near-term catalysts from earnings calls; favor firms with buybacks/guidance beats for alpha, monitor margin trends for industrials.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — May 06, 2026

Across 50 SEC filings for May 6, 2026, Q1 2026 earnings dominate with mixed results: 8/15 reporting companies showed revenue growth averaging +12% YoY (e.g., Clear Secure +19.7%, BeOne +35%), but 5/15 faced declines averaging -15% YoY (e.g., Owens Corning -10%, LP -21%), highlighting cyclical weakness in building materials vs resilience in tech/healthcare. Guidance was raised by 6 companies (e.g., Taboola revenue to $2.0-2.1B, LivaNova EPS +$0.05 midpoint), signaling confidence amid margin pressures (avg compression -100bps in mixed sentiment firms). Capital returns accelerated with dividends declared by 7 firms (e.g., Acushnet $0.255/sh, Deluxe $0.30/sh) and buybacks (Clear Secure $56M, Acushnet $10M Q1). M&A/SPAC activity surged with TWO Harbors pushing CCM deal at 14% premium (close Q3 2026), Qorvo/Skyworks merger advancing (late 2026), and 4 SPAC IPOs priced (e.g., Quantum Leap $200M). 13F filings (14 total) reveal heavy tech concentration (NVDA top in 6/14, avg 20% portfolio weight), underscoring AI enthusiasm. Building products face headwinds (OSB prices -31% YoY at LP), while healthcare/biotech shows royalty-driven gains (BeOne Amgen +231% YoY). Overall, actionable tilt to growth names with catalysts, monitor cyclicals for Q2 guidance.

18 high priority 32 medium 50 total filings